Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Ibrance
Ibrance
Drugmakers revive R&D focus on long stagnant women's health market
Medical Marketing and Media
Tue, 08/23/16 - 10:50 am
R&D
Women's Health
innovation
Myovant Sciences
Amgen
UCB Pharma
breast cancer
Pfizer
S1 Biopharma
Ibrance
Addyi
Pfizer Inc: Can New Drugs Growth Eliminate the Need for a Split-up?
Bidness, ETC
Thu, 08/4/16 - 09:40 am
Pfizer
Ibrance
Xeljanz
Pfizer's Ibrance on pace for blockbuster status after strong Q2
BioPharma Dive
Wed, 08/3/16 - 09:00 am
Pfizer
Ibrance
breast cancer
Five Storylines To Watch At ASCO
Forbes
Tue, 05/31/16 - 11:14 am
ASCO 2016
drug pricing
Pfizer
Ibrance
breast cancer
Tecentriq
Genentech
Roche
PDL-1 inhibitors
3 Stories To Watch At The Year’s Biggest Cancer Conference
Investors.com
Mon, 05/30/16 - 06:34 pm
ASCO 2016
Pfizer
Eli Lilly
breast cancer
Ibrance
abemaciclib
AbbVie
non-small cell lung cancer
Rova-T
Keytruda
Bristol-Myers Squibb
Merck
Opdivo
The mano-a-mano between Pfizer's Ibrance and Novartis' LEE011 nears with early PhIII wrap-up
Fierce Pharma
Wed, 05/18/16 - 04:27 pm
Pfizer
Ibrance
Novartis
LEE011
breast cancer
clinical trials
Pfizer Inc Cancer Drug Ibrance’s Prospects Boosted by Positive Phase 3 Data
Bidness, ETC
Wed, 04/20/16 - 12:40 pm
Pfizer
Ibrance
breast cancer
clinical trials
Pfizer an Count on Ibrance for Upside and Massive Sales
Bidness, ETC
Mon, 02/22/16 - 09:33 am
Pfizer
Ibrance
breast cancer
advanced breast cancer
Pfizer keeps pushing on early hit Ibrance as Novartis, Lilly rivals near market
Fierce Pharma Marketing
Mon, 02/8/16 - 12:48 pm
Pfizer
Ibrance
breast cancer
Novartis
Eli Lilly
Pfizer's Ibrance clears first hurdle to early access in U.K.
Fierce Pharma
Fri, 01/22/16 - 09:34 pm
Pfizer
Ibrance
UK
T-DM1. breast cancer
Cancer Drugs: Strong Growth for Bristol’s Opdivo, Pfizer’s Ibrance
Barron's
Wed, 12/30/15 - 09:01 pm
Bristol-Myers Squibb
Opdivo
Pfizer
Ibrance
Pfizer Inc.'s Best Drug in 2015
Motley Fool
Tue, 12/29/15 - 09:59 am
Pfizer
Ibrance
metastatic breast cancer
Pfizer Announces FDA Acceptance of IBRANCE® (palbociclib) Supplemental New Drug Application with Priority Review in HR+, HER2- Metastatic Breast Cancer
Yahoo
Thu, 12/10/15 - 11:20 am
Pfizer
FDA
Ibrance
priority review
metastatic breast cancer
Pfizer plots Ibrance expansion as early-stage breast cancer trial begins
Fierce Pharma
Thu, 08/27/15 - 11:48 am
Pfizer
Ibrance
breast cancer
Pfizer's hot-selling Ibrance gets even hotter with new $710M sales estimate for 2015
Fierce Pharma Marketing
Mon, 08/3/15 - 04:59 pm
Pfizer
Ibrance
breast cancer
3 Top Big Pharmaceutical Stocks With Upcoming Catalysts
24/7 Wall St
Tue, 07/14/15 - 11:44 am
AbbVie
Humira
Cyramza
Eli Lilly
generics
Evista
Cymbalta
Pfizer
Ibrance
Pfizer: New Oncology Drug Ibrance Performing Well
Seeking Alpha
Tue, 06/23/15 - 04:23 pm
Pfizer
Ibrance
Pfizer's Ibrance Takes Another Giant Leap Forward
Investopedia
Tue, 06/2/15 - 09:03 am
Pfizer
Ibrance
ASCO
breast cancer
Pfizer's breast cancer-fighter Ibrance posts stellar second-line survival data
Fierce Pharma
Sat, 05/30/15 - 05:28 pm
Pfizer
Ibrance
ASCO
breast cancer
ASCO cancer research data drop: What to watch
CNBC
Wed, 05/13/15 - 12:18 pm
ASCO
oncology
cancer
Merck
Bristol-Myers Squibb
AstraZeneca
Juno Therapeutics
CAR-T
Ibrance
Pfizer
elotuzumab
Opdivo
Keytruda
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »